Admedus makes "transformational" sale of CardioCel and VascuCel for $36.2 million
Admedus delivers results with heart-driven corporate strategy
Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.